biotech-commercialization
(2)
Akira Robinson
Akira Robinson is a biotech and pharmaceutical commercialization leader with roughly two decades of experience turning early-stage science into market-ready medicine. He is a Partner and Chief Experience Officer at the life-sciences consultancy Scimitar Inc. and serves as interim Chief Commercial Officer at Nucleus RadioPharma. He built and scaled the launch practice at EVERSANA to more than 20 consultants, and has stepped into interim CCO and COO seats across the industry. With a Harvard biochemistry degree, a Johns Hopkins biotech master's, and a stint as a Wall Street biotech equity analyst, he blends scientific fluency with commercial operating chops, lately focused on radiopharmaceutical therapies and AI-driven commercialization.
Sebby Borriello
Sebby Borriello is a pharmaceutical and medical-device commercialization veteran with 30-plus years of go-to-market leadership. After 25 years at Johnson & Johnson across wound management, biosurgery and aesthetics, he helped turn South Korea's SK Life Science from an R&D-only shop into a fully integrated US pharma company, leading the 2020 launch of its first FDA-approved drug, the epilepsy treatment XCOPRI. He later advised and joined Carmell Therapeutics as Chief Business Officer, and today serves as Executive Vice President and Chief Commercial Officer at MIDAS Healthcare Solutions, a New York startup tackling medication diversion and drug-waste accountability through its MidasVIEW platform and Anytime Witness video-verification technology.